Breast cancer is still one of the most common cancer diagnoses and remains the most commonly diagnosed in women, and surgery continues to be considered the gold standard in first line treatment of the disease. Surgery is rarely used as monotherapy however, and most patients will expect concurrent chemotherapy, radiotherapy, hormonal treatment, or pharmacotherapy with cancer targeting drug molecules. Knowing which treatment courses to use for each patient case can be difficult to identify, and identifying markers and diagnostics that can guide these decisions is pivotal in refining the breast cancer treatment cascade.
Researchers worldwide continue to find new and innovative ways of using biomarkers to analyze and determine the prognoses of patients with breast cancer, both pre and post operatively, and also find links between these biomarkers and metastases to other organs within the body. This research can provide the information necessary to revise and refine the proposed post-surgical treatment, and predict their efficacy in treating these cancers. As new treatment methods are identified and trialed, more work needs to be done to find and create meaningful links between these prognostic biomarkers and the most efficacious treatments in a way that is practical and not anecdotal, with patients eventually benefiting from tailored treatment plans based on the individual and their specific cancer, and better understanding of how the disease can develop and metastasize.
This Research Topic sets to highlight emerging research covering various types of post-operative treatment options for clinicians, as well as some of the innovative ways researchers are driving the field of surgery to treat breast cancer using new and advanced technologies previously unseen.
We welcome Original Research, leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
- Hepatectomy and liver resection surgeries
- New innovations in technologies aiding breast cancer surgery or reconstruction
- Utilization or discovery of new prognostic markers
- Chemotherapy in breast cancer
- Radiotherapy in breast cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Breast cancer is still one of the most common cancer diagnoses and remains the most commonly diagnosed in women, and surgery continues to be considered the gold standard in first line treatment of the disease. Surgery is rarely used as monotherapy however, and most patients will expect concurrent chemotherapy, radiotherapy, hormonal treatment, or pharmacotherapy with cancer targeting drug molecules. Knowing which treatment courses to use for each patient case can be difficult to identify, and identifying markers and diagnostics that can guide these decisions is pivotal in refining the breast cancer treatment cascade.
Researchers worldwide continue to find new and innovative ways of using biomarkers to analyze and determine the prognoses of patients with breast cancer, both pre and post operatively, and also find links between these biomarkers and metastases to other organs within the body. This research can provide the information necessary to revise and refine the proposed post-surgical treatment, and predict their efficacy in treating these cancers. As new treatment methods are identified and trialed, more work needs to be done to find and create meaningful links between these prognostic biomarkers and the most efficacious treatments in a way that is practical and not anecdotal, with patients eventually benefiting from tailored treatment plans based on the individual and their specific cancer, and better understanding of how the disease can develop and metastasize.
This Research Topic sets to highlight emerging research covering various types of post-operative treatment options for clinicians, as well as some of the innovative ways researchers are driving the field of surgery to treat breast cancer using new and advanced technologies previously unseen.
We welcome Original Research, leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
- Hepatectomy and liver resection surgeries
- New innovations in technologies aiding breast cancer surgery or reconstruction
- Utilization or discovery of new prognostic markers
- Chemotherapy in breast cancer
- Radiotherapy in breast cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
